Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;281(1):369-377.
doi: 10.1007/s00405-023-08187-3. Epub 2023 Aug 18.

A predictive survival model for patients with stage IV oropharyngeal squamous cell carcinoma treated with chemoradiation

Peng Yeh  1 , Chih-Ming Chang  1   2 , Li-Jen Liao  1   3   4 , Chia-Yun Wu  3   5 , Chen-Hsi Hsieh  3   6   7 , Pei-Wei Shueng  6   7 , Po-Wen Cheng  1 , Wu-Chia Lo  8   9   10
Affiliations

A predictive survival model for patients with stage IV oropharyngeal squamous cell carcinoma treated with chemoradiation

Peng Yeh et al. Eur Arch Otorhinolaryngol. 2024 Jan.

Abstract

Purpose: To evaluate the pre-treatment and post-treatment clinical factors associated with rate of survival at 1, 3, and 5 years in stage IV oropharyngeal cancer patients treated with concurrent chemoradiation with/without neoadjuvant chemotherapy.

Methods: This retrospective cohort study involved 128 Stage IV oropharyngeal cancer patients that were treated at our tertiary referral center between 2008 and 2020. The pre-treatment and post-treatment clinical parameters including nutritional status and inflammatory markers were retrospectively reviewed.

Results: The 5-year overall survival rate for all patients was 36.72%. The disease-specific survival (DSS) at 1-year and 3-year were 80% and 63%, whereas the disease-free survival (DFS) at 1-year and 3-year were 49% and 40%, respectively. In multivariate analyses, pretreatment hemoglobin (Hb) < 12 g/dL (hazard ratio [HR] 2.551, 95% confidence interval [CI] 1.366-4.762, p = 0.003), pretreatment systemic immune inflammation (SII) ≥ 1751 (HR 2.173, 95% CI 1.015-4.652, p = 0.046), and posttreatment systemic inflammation response index (SIRI) ≥ 261 (HR 2.074, 95% CI 1.045-4.115, p = 0.037) were independent indicators for worsened DSS. Pretreatment Hb < 12 g/dl (HR 1.692, 95% CI 1.019-2.809, p = 0.032), pretreatment SII ≥ 1751 (HR 1.968, 95% CI 1.061-3.650, p = 0.032), and posttreatment SII ≥ 1690 (HR 1.922, 95% CI 1.105-3.345, p = 0.021) were independent indicators for worsened DFS. A nomogram was developed using pretreatment Hb, pretreatment SII, and posttreatment SIRI to forecast DSS.

Conclusions: The pretreatment Hb, pretreatment SII, posttreatment SII, and posttreatment SIRI are associated with survival in patients with stage IV oropharyngeal cancers. The developed nomogram aids in survival prediction and treatment adjustment.

Keywords: Chemoradiation; Hemoglobin; Nomogram; Oropharyngeal cancer; Systemic immune inflammation; Systemic inflammation response index.

PubMed Disclaimer

References

    1. Ferlay J, Colombet M, Soerjomataram I et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941–1953 - DOI - PubMed
    1. Dahlstrom KR, Calzada G, Hanby JD et al (2013) An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. Cancer 119:81–89 - DOI - PubMed
    1. Wang C-P, Chen T-C, Hsu W-L et al (2022) Rising incidence of HPV positive oropharyngeal cancer in Taiwan between 1999 and 2014 where betel nut chewing is common. BMC Cancer 22:296 - DOI - PubMed - PMC
    1. Damgacioglu H, Sonawane K, Chhatwal J et al (2022) Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study. Lancet Reg Health Am 8:100143 - PubMed
    1. Chaturvedi AK, Engels EA, Pfeiffer RM et al (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29:4294–4301 - DOI - PubMed

LinkOut - more resources